Skip to content

CninMed – China Innovative Drugs Update

  • Contact Us
  • Latest

[China BD 2025] Hengrui and Braveheart Bio (NewCo) enters a 1 billion USD license on Myosin inhibitor HRS-1893

September 5, 2025September 5, 2025

[China BD 2025] Argo Biopharma and Novartis enters License and Option on Four siRNA Programs

September 3, 2025September 4, 2025

[China BD 2025] Novatim and Radiance enters a 1 billion USD license on MET/EGFR BsADC KY-0301

September 2, 2025September 2, 2025

[China BD Deal] Fosun and Sitala enters a 670 million license on CFBi FXS6837

August 27, 2025August 31, 2025
View More
Posted in
  • China License Out
  • China NewCo

[China BD 2025] Hengrui and Braveheart Bio (NewCo) enters a 1 billion USD license on Myosin inhibitor HRS-1893

Announced Date: 2025-09-05 (September 5, 2025) Asset Name: HRS-1893 Licensor: Jiangsu Hengrui Pharmaceuticals (China) Licensee (Buyer): … [China BD 2025] Hengrui and Braveheart Bio (NewCo) enters a 1 billion USD license on Myosin inhibitor HRS-1893Read more

by admin•September 5, 2025September 5, 2025•0
Posted in
  • China License Out

[China BD 2025] Argo Biopharma and Novartis enters License and Option on Four siRNA Programs

Announced Date: 2025-09-03 (September 3, 2024) Asset Name: Four siRNA programs  Licensor: Shanghai Argo Biopharmaceutical (China) … [China BD 2025] Argo Biopharma and Novartis enters License and Option on Four siRNA ProgramsRead more

by admin•September 3, 2025September 4, 2025•0
Posted in
  • China License Out

[China BD 2025] Novatim and Radiance enters a 1 billion USD license on MET/EGFR BsADC KY-0301

Announced Date: 2025-08-29 (August 29, 2025) Asset Name: KY-0301 Licensor: Novatim (Novatim Immune Therapeutics, China) Licensee … [China BD 2025] Novatim and Radiance enters a 1 billion USD license on MET/EGFR BsADC KY-0301Read more

by admin•September 2, 2025September 2, 2025•0
Posted in
  • China License Out

[China BD Deal] Fosun and Sitala enters a 670 million license on CFBi FXS6837

Announced Date: 2025-08-26 (August 26, 2025) Asset Name: FXS6837 (Other code: XH-S003) Licensor: Fosun Pharma and … [China BD Deal] Fosun and Sitala enters a 670 million license on CFBi FXS6837Read more

by admin•August 27, 2025August 31, 2025•0
Posted in
  • China License Out

[China BD Deal] RemeGen and Santen enters a 1.3 billion RMB license on Anti-VEGF/FGF Fusion Protein RC28-E

Announced Date: 2025-08-19 (August 19, 2025) Asset Name: RC28-E Intravitreal Injection Licensor: RemeGen (RemeGen Co., Ltd., … [China BD Deal] RemeGen and Santen enters a 1.3 billion RMB license on Anti-VEGF/FGF Fusion Protein RC28-ERead more

by admin•August 19, 2025August 31, 2025•0
Posted in
  • China License Out

[China BD Deal] Fosun and Expedition achieved a 645 million license on DPP-1 i XH-S004

Announced Date: 2025-08-11 (August 11, 2025) Asset Name: XH-S004 Licensor: Shanghai Fosun Pharmaceutical (Group) Co., Ltd. … [China BD Deal] Fosun and Expedition achieved a 645 million license on DPP-1 i XH-S004Read more

by admin•August 11, 2025August 11, 2025•0
Posted in
  • China Tech Corp

[Technology Collaboration] XtalPi and Dovetree enters a 6 billion USD Collaboration on AI drug discovery

Announced Date: 2025-08-05 (August 5, 2025) Licensor: XtalPi Inc. (China) Licensee: DoveTree Medicines(US) . Scope of … [Technology Collaboration] XtalPi and Dovetree enters a 6 billion USD Collaboration on AI drug discoveryRead more

by admin•August 6, 2025September 10, 2025•0
Posted in
  • China License Out

[China BD Deal] CSPC and Madrigal achieved a 2 billion license on GLP-1 R SYH2086

Announced Date: 2025-07-30 (JULY 30, 2025) Asset Name: SYH2086 Licensor: CSPC Pharmaceutical Group Limited (HKEX Stock … [China BD Deal] CSPC and Madrigal achieved a 2 billion license on GLP-1 R SYH2086Read more

by admin•July 30, 2025July 30, 2025•0
Posted in
  • China License Out

[China BD 2025] Hengrui and GSK  achieved a 12.5 billion USD license on PDE3/4 inhibitor HRS-9821 and 11 other assets

Announced Date: 2025-07-28 (JULY 28, 2025) Asset Name: HRS-9821 and other 11 preclinical medicines Licensor: Hengrui … [China BD 2025] Hengrui and GSK  achieved a 12.5 billion USD license on PDE3/4 inhibitor HRS-9821 and 11 other assetsRead more

by admin•July 30, 2025September 7, 2025•0
Posted in
  • China License Out

[China BD Deal] 3SBio and Pfizer Completes a 6 billion License on PD-1/VEGF BsAbs SSGJ-707

Announced Date: 2025-05-19 (May 19, 2025), 2025-07-24 updated Asset Name: SSGJ-707 Licensor: 3SBio, Inc (01530.HK) (Headquarter Shanghai … [China BD Deal] 3SBio and Pfizer Completes a 6 billion License on PD-1/VEGF BsAbs SSGJ-707Read more

by admin•July 12, 2025July 30, 2025•0

Posts pagination

1 2 … 9 Next

Recent Posts

  • [China BD 2025] Hengrui and Braveheart Bio (NewCo) enters a 1 billion USD license on Myosin inhibitor HRS-1893
  • [China BD 2025] Argo Biopharma and Novartis enters License and Option on Four siRNA Programs
  • [China BD 2025] Novatim and Radiance enters a 1 billion USD license on MET/EGFR BsADC KY-0301
  • [China BD Deal] Fosun and Sitala enters a 670 million license on CFBi FXS6837
  • [China BD Deal] RemeGen and Santen enters a 1.3 billion RMB license on Anti-VEGF/FGF Fusion Protein RC28-E

Recent Comments

  1. [Technology Collaboration] MediLink and BioNTech Expand the Collaboration on several ADC products – CninMed – China Innovative Drugs Update on [China BD 2023] MediLink and BioNTech enters a 1 billion USD License on HER3 ADC YL202 (BNT326)
  2. [China Original Asset] BioNTech and BMS enters a 11.1 billion USD Collaboration on PD-L1xVEGF-A BsAbs BNT327 (PM8002 from Biotheus) – CninMed – China Innovative Drugs Update on [China BD 2024] Biotheus and BioNTech Enters an Acquisition on PD-L1/VEGF-A BsAbs PM8002 (BNT327)
  3. admin on [China BD Deal] TUL and Novo Nordisk enters a 2 billion USD license for UBT251, a GLP-1/GIP/glucagon triple receptor agonist

Categories

  • China FIC Drug
  • China License Out
  • China NewCo
  • China Original Asset
  • China Tech Corp
Copyright © 2025 CninMed - China Innovative Drugs Update.
Powered by WordPress and HybridMag.
  • Contact Us